137864-23-4

Basic information

• Product Name: N-[(2'-Cyano Biphenyl-4-yl) Methyl-L-Valine Benzyl Ester
• Synonyms: N-[(2'-Cyano Biphenyl-4-yl) Methyl-L-Valine Benzyl Ester;N-[(2'-Cyano[1,1'-biphenyl]-4-yl)methyl]-L-valine phenylmethyl ester
• CAS NO: 137864-23-4
• Molecular Formula: C₂₆H₂₆N₂O₂
• Molecular Weight: 398.49684
• Mol File: 137864-23-4.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-[(2'-Cyano Biphenyl-4-yl) Methyl-L-Valine Benzyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-[(2'-Cyano Biphenyl-4-yl) Methyl-L-Valine Benzyl Ester(137864-23-4)
• EPA Substance Registry System: N-[(2'-Cyano Biphenyl-4-yl) Methyl-L-Valine Benzyl Ester(137864-23-4)

Safety Data

• Hazardous Substances Data: 137864-23-4(Hazardous Substances Data)

Usage

General Description

N-[(2'-Cyano Biphenyl-4-yl) Methyl-L-Valine Benzyl Ester, also known as Cilastatin, is a chemical compound with potential pharmaceutical applications. It is a prodrug of the antibiotic Imipenem, and it is commonly used in combination with Imipenem to increase its half-life and efficacy. Cilastatin works by inhibiting the renal enzyme dehydropeptidase I, which breaks down Imipenem, thereby prolonging its activity within the body. This combination drug is primarily used to treat severe bacterial infections in hospital settings, including urinary tract infections, respiratory tract infections, and intra-abdominal infections. Additionally, Cilastatin may have potential applications in other fields of medicine, such as in the treatment of cystic fibrosis and sepsis.

Upstream product

• 21760-98-5 L-valine benzyl ester 
• 114772-54-2 4'-(bromomethyl)-1,1'-biphenyl-2-carbonitrile 
• 137864-24-5 (S)-2-[(2'-cyanobiphenyl-4-ylmethyl)amino]-3-methylbutyric acid benzyl ester hydrochloride 

Downstream Products

• 137864-57-4 N-carboethoxy-N-[(2'-cyanobiphenyl-4-yl)methyl]-(L)-valine benzyl ester 
• 137864-22-3 (S)-2-[(2'-cyanobiphenyl-4-ylmethyl)pentanoylamino]-3-methylbutyric acid benzyl ester 
• 188240-32-6 (S)-N-(4-Oxo-valeryl)-N-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]valine benzyl ester 
• 188259-69-0 4-Hydroxyvalsartan 
• 188240-33-7 (S)-N-(4-Oxo-valeryl)-N-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]valine 
• 188240-31-5 (S)-N-(4-Oxo-valeryl)-N-[(2'-cyano-biphenyl-4-yl)methyl]valine benzyl ester 

Relevant articles and documents

PROCESS FOR PREPARATION OF 5-SUBSTITUTED TETRAZOLES

The present invention is a process for preparing sterically hindered 5-substituted tetrazole, which comprises of reacting a nitrile with an organotin halide and an azide in presence of a phase transfer catalyst, in an organic solvent and a co- solvent at reflux temperature for 4 to 20 h.

ACYL COMPOUNDS

Compounds of the formula STR1 in which R 1 is an aliphatic hydrocarbon radical which is unsubstituted or substituted by halogen or hydroxyl, or a cycloaliphatic or araliphatic hydrocarbon radical; X 1 is CO, SO 2, or--O--C(=O)--with the carbon atom of the carbonyl group being attached to the nitrogen atom shown in formula I; X 2 is a divalent aliphatic hydrocarbon radical which is unsubstituted or substituted by hydroxyl, carboxyl, amino, guanidino or a cycloaliphatic or aromatic radical, or is a divalent cycloaliphatic hydrocarbon radical, it being possible for a carbon atom of the aliphatic hydrocarbon radical to be additionally bridged by a divalent aliphatic hydrocarbon radical; R. sub.2 is carboxyl which, if desired, is esterified or amidated, substituted or unsubstituted amino, formyl which, if desired, is acetalized, 1H-tetrazol-5-yl, pyridyl, hydroxyl which, if desired, is etherified, S(O) m--R where m is 0, 1 or 2 and R is hydrogen or an aliphatic hydrocarbon radical, alkanoyl, unsubstituted or N-substituted sulfamoyl or PO n H 2 where n is 2 or 3; X 3 is a divalent aliphatic hydrocarbon; R 3 is carboxyl, 5-tetrazolyl, SO. sub.3 H, PO. sub.2 H 2, PO 3 H 2 or haloalkylsulfamoyl; and the rings A and B independently of one another are substituted or unsubstituted; in free form or in salt form, can be prepared in a manner known per se and can be used, for example, as medicament active ingredients.